Mobile

Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003532-30

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary endpoint of this study is the response rate according to the IPS score based on the comparison of the results of the baseline visit (V2) and after 12 months (V7)

Critère d'inclusion

  • Benign Prostate Hyperplasia

Liens